Literature DB >> 445961

Piperacillin kinetics.

V K Batra, J A Morrison, K C Lasseter, V A Joy.   

Abstract

Piperacillin was administered to normal, healthy volunteers by an intravenous infusion over 30 min at dosage regimens of 12 gm daily (4 gm every 8 hr) and 24 gm daily (6 gm every 6 hr) for 5 consecutive days. Mean peak serum level after 12 gm daily was 244 +/- 24 (SE) microgram/ml and after 24 gm daily, 353 +/- 7 microgram/ml. After infusion the serum level declined monoexponentially in most subjects. On the 12-gm daily dosage mean values were 60 min for half-life (t1/2), 16 1 for volume of distribution, 188 ml/min for body clearance, and 139 ml/min for renal clearance. The same values on day 4 were 47 min, 12 1, 181 ml/min, and 125 ml/min; the volume of distribution was lower than on day 1. On the 24-gm daily dosage regimen, t1/2 was 60 min; volume of distribution, 16 1; body clearance, 183 ml/min; and renal clearance, 101 ml/min on day 1 compared to 68 min, 15 1, 148 ml/min, and 71 ml/min on day 4, the last 2 being significantly lower than on day 1. High renal clearance values were observed at low serum concentrations and vice versa, suggesting saturation of the tubular secretion process at high piperacillin concentrations in serum.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 445961     DOI: 10.1002/cpt197926141

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

1.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 3.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

4.  Comparative pharmacokinetics of azlocillin and piperacillin in normal adults.

Authors:  P A Colaizzi; R E Polk; W J Poynor; A C Raffalovich; E A Cefali; L A Beightol
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

5.  Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.

Authors:  J E Tisdale; M T Pasko; J M Mylotte
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Penetration of piperacillin into bronchial mucosa and sputum.

Authors:  G E Marlin; K R Burgess; J Burgoyne; G R Funnell; M D Guinness
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

7.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

8.  Comparative pharmacokinetics of 14C-piperacillin following intravenous and intraperitoneal administration in pregnant and non-pregnant rats.

Authors:  V Batra; J Morrison; E Kaleita
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

9.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.